证券代码：301130 证券简称：西点药业 公告编号：2023-049 吉林省西点药业科技发展股份有限公司 关于公司药品生产许可证变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 吉林省西点药业科技发展股份有限公司（以下简称"公司"）于 2023 年 7 月向吉林省药品监督管理局提交申请变更《药品生产许可证》申报材料，近日完 成了变更登记手续，收到吉林省药品监督管理局颁发的《药品生产许可证》（许 可证编号：吉 20160071），本次主要涉新增生产范围。具体变更登记事项如下： 一、变更内容 （一）新增生产范围：同意该企业《药品生产许可证》变更生产范围(现有 生产地址增加生产范围):在生产地址 1:吉林省磐石经济开发区西点大街 777 号 增加生产范围:口服溶液剂，生产车间和生产线:口服液一车间口服溶液生产线。 在生产地址 2:吉林市龙潭区汉江路 2 号增加生产范围:原料药 (枸橼酸钙)，生 产车间和生产线：合成二车间车间原料药生产线；原料药(蛋白琥珀酸铁)，生产 车间和生产线：合成三车间车间原料药生产线。(以下空白) 二、变更后的《药品生产许可证》具 ...

证券代码： 301130 证券简称：西点药业 吉林省西点药业科技发展股份有限公司投资者关系活动记 录表 | --- | --- | --- | |----------------|----------------------------------|--------------------| | 投资者关系活动 | □特定对象调研 | | | 类别 | □ 媒体采访 | | | | □ 新闻发布会 | | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称及 | 投资者网上提问 | | | 人员姓名 | | | | 时间 | 2023 年 5 月 22 日 | | | 地点 | | https://ir.p5w.net | | | 采用网络远程的方式召开业绩说明会 | | | 上市公司接待人 | 1、董事长 张俊 | | | 员姓名 | 2、副总经理 石英秀 | | | | 3、财务总监 吕大伟 | | | | 4、董事会秘书 | | | | 5、保荐代表人 | | 6、独立董事 张士宇 投资者提出的问题及公司回复情况 公司就投资者在本次说明会中提出的问题进行了回复： 1、请问贵公司一季 ...

关于参加网上集体业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 吉林省西点药业科技发展股份有限公司（以下简称"公司"）已于 2023 年 4 月 21 日巨潮资讯网 (www.cninfo.com.cn)上披露了《2022 年年度报告》及 《2022 年度报告摘要》。 证券代码：301130 证券简称：西点药业 公告编号：2023-026 吉林省西点药业科技发展股份有限公司 特此公告。 吉林省西点药业科技发展股份有限公司董事会 2023 年 5 月 15 日 为进一步加强与投资者的互动交流，公司将参加由吉林证监局、吉林省证券 业协会、深圳市全景网络有限公司共同举办的"2023 年吉林辖区上市公司网上 集体业绩说明会"，现将有关事项公告如下： 本次集体业绩说明会将通过深圳市全景网络有限公司提供的互联网平台举 行，投资者可以登陆"全景网"投资者关系互动平台"（http://ir.p5w.net） 参与公司业绩说明会,时间为 2023 年 5 月 22 日（星期一）14:00 至 16:00。 届时公司董事长、总经理张俊先生，公司董事、副总经理、董 ...

Financial Performance - The company's revenue for Q1 2023 was CNY 55,440,064.10, representing a 4.39% increase compared to CNY 53,106,464.55 in the same period last year[5]. - Net profit attributable to shareholders for Q1 2023 was CNY 9,575,298.60, a 21.11% increase from CNY 7,906,004.78 year-on-year[5]. - The basic and diluted earnings per share for Q1 2023 were both CNY 0.1185, reflecting a 0.94% increase from CNY 0.1174 in the same period last year[5]. - The net profit excluding non-recurring gains and losses was CNY 6,340,660.01, down 17.50% from CNY 7,685,745.09 in the same period last year[5]. - The total operating revenue for the first quarter was CNY 55,440,064.10, an increase of 4.38% compared to CNY 53,106,464.55 in the previous period[19]. - The total profit for the first quarter was CNY 11,041,756.84, up from CNY 9,178,658.59, indicating a growth of 20.2% year-over-year[21]. - The operating profit for the first quarter was CNY 11,043,044.54, compared to CNY 10,184,421.59 in the previous year, reflecting a growth of 8.4%[21]. Cash Flow and Assets - The net cash flow from operating activities was negative CNY 632,674.43, a decline of 104.05% compared to a positive CNY 15,610,919.58 in the previous year[5][7]. - Cash flow from operating activities showed a net outflow of CNY -632,674.43, a significant decrease from a net inflow of CNY 15,610,919.58 in the previous year[23]. - The total cash inflow from operating activities was CNY 66,226,632.51, compared to CNY 72,373,547.26 in the same period last year, indicating a decline of 8.4%[23]. - Cash flow from investing activities generated a net inflow of CNY 8,630,145.46, down from CNY 64,048,790.21 in the same period last year[24]. - The company reported cash and cash equivalents at the end of the period amounting to CNY 210,218,274.10, a decrease from CNY 637,080,557.42 at the end of the previous year[24]. - Cash and cash equivalents increased to CNY 210,777,522.66 from CNY 202,779,648.02, showing a growth of 3.92%[17]. - Inventory rose to CNY 26,853,993.22, up 29.73% from CNY 20,701,630.93 at the beginning of the year[17]. - Total assets at the end of Q1 2023 were CNY 1,011,580,716.26, a decrease of 0.53% from CNY 1,017,003,454.64 at the end of the previous year[5]. - The total assets decreased to CNY 1,011,580,716.26 from CNY 1,017,003,454.64 at the beginning of the year, a decline of 0.53%[17]. Shareholder Information - The company reported a total of 10,339 common shareholders at the end of the reporting period[9]. - The top shareholder, Zhang Jun, holds 24.29% of the shares, amounting to 19,627,034 shares[9]. - The number of restricted shares released on February 23, 2023, was 40,975,923 shares, accounting for 50.71% of the total share capital after the company's issuance[15]. - The remaining restricted shares not yet released amount to 19,627,034 shares, representing 24.29% of the total share capital after the company's issuance[15]. - The total number of shareholders who had their restricted shares released was 17[15]. - The company has a total of 60,602,957 restricted shares, with 37,827,148 shares released during the reporting period[13]. - The largest shareholder, Zhang Jun, holds 19,627,034 shares, which are restricted until February 23, 2025[13]. - The second-largest shareholder, Dingdian Investment Management, holds 7,639,054 shares, which were fully released on February 23, 2023[13]. - Guo Hongsheng, another significant shareholder, holds 3,021,550 shares, all of which are restricted until February 23, 2023[13]. - The company has not engaged in any financing or securities lending activities with its top 10 shareholders[13]. - The report indicates that the company has a consistent shareholder structure with several investment management firms involved[15]. - The company is focused on maintaining a stable capital structure while managing the release of restricted shares effectively[15]. Operating Costs and Expenses - The total operating costs amounted to CNY 47,961,292.11, up 7.06% from CNY 44,475,693.43 in the prior year[19]. - Research and development expenses were CNY 1,493,602.36, a decrease of 7.63% from CNY 1,616,947.44 in the prior year[19]. - The company reported a gross profit margin of approximately 13.36% for the quarter, compared to 16.51% in the previous period[19]. Other Information - The company received government subsidies amounting to CNY 790,620.76, which were closely related to its normal business operations[6]. - The company did not conduct an audit for the first quarter report[25].

Financial Performance - The company's operating revenue for 2022 was ¥255,467,987.43, a decrease of 10.57% compared to ¥285,655,932.11 in 2021[22]. - The net profit attributable to shareholders for 2022 was ¥40,723,025.38, down 21.72% from ¥52,019,092.21 in the previous year[22]. - The net profit after deducting non-recurring gains and losses was ¥33,633,860.81, a decline of 25.25% from ¥44,997,813.13 in 2021[22]. - The basic earnings per share for 2022 were ¥0.5259, a decrease of 38.73% from ¥0.8584 in 2021[22]. - The company's total revenue for 2022 was ¥255,467,987.43, a decrease of 10.57% compared to ¥285,655,932.11 in 2021[72]. - The net profit attributable to shareholders was ¥40,723,025.38, down 21.72% from the previous year[72]. - The main pharmaceutical business contributed ¥255,397,667.63, accounting for 99.97% of total revenue, with a decrease of 10.43% from the previous year[74]. - The revenue from compound ferrous sulfate tablets was ¥127,441,382.47, representing 49.89% of total revenue, down 15.97% from ¥151,656,589.29[74]. - The revenue from risperidone orally disintegrating tablets was ¥86,789,150.47, which increased by 1.15% compared to the previous year[74]. - The revenue from escitalopram oxalate tablets rose by 31.87% to ¥11,452,434.97, compared to ¥8,684,359.79 in 2021[74]. Dividend Distribution - The company plans to distribute a cash dividend of 1.60 RMB per 10 shares to all shareholders, based on a total of 80,803,943 shares[3]. - The cash dividend proposed is CNY 1.60 per 10 shares, totaling CNY 12,928,630.88, which represents 100% of the profit distribution[161][163]. - The company maintains a stable and active profit distribution policy, prioritizing cash dividends while considering sustainable development[160]. Market Overview - The global pharmaceutical market size was $1,387.5 billion in 2021 and is expected to reach $1,681.6 billion by 2025, with a CAGR of 5.4%[32]. - The Chinese pharmaceutical market size was ¥1,650.1 billion in 2021, projected to grow to ¥2,287.3 billion by 2025, reflecting a CAGR of 9.3%[34]. - The chemical drug market in China reached ¥846.6 billion in 2021 and is anticipated to grow to ¥1,143.8 billion by 2030[35]. - The market for anti-anemia drugs in China was valued at ¥26.45 billion in 2021, showing a year-on-year growth of 2%[40]. Product Performance - The company's core product, Yiyuan Sheng, ranked sixth in the top ten iron supplement products in Chinese urban pharmacies, with a market share of 5.6%[43]. - The online pharmacy market for iron supplements saw Yiyuan Sheng ranked fifth, with a growth rate of 98.86%[43]. - The company holds over 90% market share in the risperidone orally disintegrating tablet market in China, with three manufacturers approved for production[44]. - The company’s product Yiyuan Sheng is positioned in the oral solid dosage form for treating iron deficiency anemia, indicating stable growth prospects[43]. Research and Development - Research and development investment amounted to ¥11,742,523.72, a reduction of 11.80% year-on-year[72]. - The company has increased its R&D personnel by 4.17% to 50, with a higher proportion of bachelor's degree holders rising to 60%[85]. - The company is actively involved in the development of new drugs, particularly in the fields of cardiovascular and anti-tumor medications, to expand its product offerings[59]. - The company is focusing on the industrialization of new products, including the development of Iron Protein Succinate and its oral liquid[84]. Regulatory Environment - The company highlights risks including concentrated core product risks, policy risks from pharmaceutical system reforms, market competition risks, and fluctuations in the supply and prices of raw materials[3]. - The implementation of the DRG/DIP payment reform is expected to promote refined management in hospitals and control healthcare costs[50]. - The revised Drug Administration Law encourages the development of pediatric and rare disease drugs, providing market exclusivity for new pediatric formulations[51]. Environmental Compliance - The company is classified as a key pollutant discharge unit by environmental protection authorities[171]. - The company has implemented measures to manage waste emissions, including waste gas, wastewater, and noise[171]. - The company has received multiple environmental impact report approvals for projects including solid preparation workshop capacity expansion and raw material drug production[172]. - The company has implemented measures to monitor and control wastewater emissions to meet environmental standards[174]. Corporate Governance - The company has established a comprehensive governance structure in compliance with relevant laws and regulations, enhancing operational standards and governance levels[126]. - The company has a fully independent financial accounting system, enabling it to make autonomous financial decisions without shared bank accounts with controlling entities[131]. - The company has a diverse board with members having backgrounds in engineering, pharmacy, and finance, enhancing its governance structure[138]. Future Outlook - The company provided a positive outlook for 2023, projecting a revenue growth of 10% to 1.32 billion yuan, driven by new product launches and market expansion strategies[142]. - The company plans to expand its market presence in Southeast Asia, targeting a 15% market share by 2025[142]. - The company aims to improve operational efficiency, targeting a 5% reduction in production costs by implementing advanced manufacturing technologies[142]. - The company is committed to sustainability, with plans to reduce carbon emissions by 30% by 2025 through eco-friendly practices[142].

吉林省西点药业科技发展股份有限公司 2022 年第三季度报告 证券代码：301130 证券简称：西点药业 公告编号：2022-033 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是 否 1 吉林省西点药业科技发展股份有限公司 2022 年第三季度报告 一、主要财务数据 吉林省西点药业科技发展股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 67,589,032.6 ...

Financial Performance - The company's revenue for the first half of 2022 was CNY 116,625,075.79, a decrease of 14.31% compared to CNY 136,103,664.27 in the same period last year[25]. - Net profit attributable to shareholders was CNY 20,735,846.86, down 10.17% from CNY 23,082,387.99 year-on-year[25]. - Basic earnings per share decreased by 26.52% to CNY 0.2799 from CNY 0.3809 in the same period last year[25]. - The company's operating revenue for the reporting period was ¥116,625,075.79, a decrease of 14.31% compared to ¥136,103,664.27 in the same period last year, primarily due to the impact of the COVID-19 outbreak in Jilin province[62]. - The company's operating costs decreased by 5.63% to ¥20,603,777.07 from ¥21,831,895.60, reflecting the decline in operating revenue[62]. - Research and development expenses dropped significantly by 63.14% to ¥2,896,216.66 from ¥7,856,797.14, due to delays in R&D activities caused by the pandemic[62]. - The net profit attributable to the parent company for the first half of 2022 was CNY 20,735,846.86, a decrease of 10.0% compared to CNY 23,082,387.99 in the same period of 2021[175]. - The basic and diluted earnings per share for the first half of 2022 were CNY 0.2799, down from CNY 0.3809 in the first half of 2021, reflecting a decline of 26.5%[175]. Cash Flow and Investments - The net cash flow from operating activities increased by 47.98% to CNY 34,600,350.11 from CNY 23,381,179.34 in the previous year[25]. - The net cash flow from financing activities surged to ¥382,329,257.51, a dramatic increase of 6,113,504.45% compared to -¥6,253.95, due to funds raised from the initial public offering[62]. - The company's cash and cash equivalents increased by 197.84% to ¥45,592,863.60 from ¥15,308,026.25, primarily due to the funds raised from the IPO[62]. - The company reported cash inflow from investment activities of CNY 65,486,573.97, while cash outflow was CNY 436,823,317.99, resulting in a net cash outflow of CNY 371,336,744.02[177]. - The total amount of funds raised through the initial public offering was CNY 455,532,200, with a net amount of CNY 390,933,100 after deducting various issuance costs[79]. - The company has cumulatively used CNY 613,500 of the raised funds, leaving a balance of CNY 378,302,700, including interest generated from the raised funds[79]. Assets and Liabilities - Total assets increased by 66.63% to CNY 990,776,059.11 from CNY 594,606,181.26 at the end of the previous year[26]. - Net assets attributable to shareholders rose by 76.54% to CNY 925,302,447.81 from CNY 524,138,056.37 at the end of the previous year[26]. - The company's total liabilities decreased to CNY 65,473,611.30 from CNY 70,468,124.89, a reduction of 7.1%[172]. - Shareholders' equity rose to CNY 925,302,447.81 as of June 30, 2022, up from CNY 524,138,056.37 at the beginning of the year, reflecting a growth of 76.5%[172]. Market and Product Development - The company is focused on the development of new drugs and technologies, although specific details are not provided in the excerpts[14]. - The company has 22 registered formulation varieties and 16 registered raw material drug varieties, focusing on anemia treatment and mental disorder medications[38]. - The company’s core product in the anemia treatment market had a market size of CNY 26.45 billion in 2021, showing a year-on-year growth of 2%[42]. - The top ten brands in the anemia treatment market hold approximately 73% market share, with key products including Hongyuanda, Sentieneng, and the company's Yiyuan Sheng[43]. - The company is actively pursuing new product development and quality standard enhancements to maintain its market position and expand its product offerings[52]. Risk Management - The company emphasizes the importance of investors being aware of potential risks and challenges in its operations[3]. - The report includes a section on risks and countermeasures, which is crucial for investor awareness[3]. - The company faces risks from medical system reforms, which may increase operational costs and affect business performance if not adapted to timely[90]. - The ongoing COVID-19 pandemic has impacted production and sales, particularly affecting the sales of its main product, a treatment for anemia[91]. - Fluctuations in raw material prices pose a risk to the company's production costs and profit margins[94]. Corporate Governance and Compliance - The financial report is guaranteed to be true, accurate, and complete by the company's management, including the chairman and accounting heads[3]. - The company has continuously improved its governance structure to protect the rights of investors[111]. - The company has not experienced any major litigation or arbitration matters during the reporting period[125]. - The company has not engaged in any related party transactions during the reporting period[126]. - The company has maintained compliance with environmental regulations, with no major environmental accidents reported during the reporting period[110]. Environmental Management - The company has implemented effective management of wastewater, waste gas, solid waste, and noise pollution, ensuring compliance with environmental regulations[105]. - The company employs noise reduction measures, including sound insulation and vibration reduction, to minimize operational noise[105]. - The company has invested in various environmental protection equipment, ensuring normal operation of its environmental facilities[109]. - The company has established a comprehensive quality assurance system to protect consumer rights and ensure high-quality products[115]. Shareholder Information - The total number of shares increased from 60,602,957 to 61,644,401 due to the issuance of new shares[146]. - The company has a diverse shareholder base, with both individual and institutional investors represented[156]. - The total number of common shareholders at the end of the reporting period is 18,853[154]. - Zhang Jun, a domestic individual, holds 24.29% of the shares, totaling 19,627,034 shares[154]. - The company has not reported any share buyback activities or changes in restricted shares during the reporting period[150].

Financial Performance - The company's revenue for Q1 2022 was ¥53,106,464.55, a decrease of 14.66% compared to ¥62,227,442.74 in the same period last year[3] - Net profit attributable to shareholders was ¥7,906,004.78, down 25.22% from ¥10,572,246.52 year-on-year[3] - Basic and diluted earnings per share were both ¥0.1174, reflecting a decrease of 32.72% from ¥0.1745 in the same period last year[3] - Total operating revenue for Q1 2022 was CNY 53,106,464.55, a decrease of 14.5% compared to CNY 62,227,442.74 in the same period last year[22] - Net profit for Q1 2022 was CNY 7,906,004.78, representing a decline of 25.3% from CNY 10,572,246.52 in Q1 2021[24] - Earnings per share for Q1 2022 was CNY 0.1174, down from CNY 0.1745 in the previous year[25] Cash Flow and Liquidity - The net cash flow from operating activities increased significantly to ¥15,610,919.58, a 683.96% improvement from -¥2,673,267.98 in the previous year[3] - The company's cash and cash equivalents amounted to RMB 637,637,486.24, up from RMB 148,630,019.72 at the beginning of the year, reflecting a substantial growth in liquidity[19] - The net cash flow from operating activities was 15,610,919.58 CNY, a significant improvement compared to -2,673,267.98 CNY in the previous year[28] - The net cash flow from investing activities was 64,048,790.21 CNY, recovering from a negative cash flow of -1,884,270.00 CNY in the same period last year[28] - The net cash flow from financing activities amounted to 409,347,756.73 CNY, indicating strong capital inflow[29] - The total cash and cash equivalents at the end of the period reached 637,080,557.42 CNY, up from 102,623,538.74 CNY year-over-year[29] - The cash flow from operating activities showed a positive trend, indicating improved operational efficiency[28] Assets and Equity - Total assets at the end of the reporting period reached ¥1,002,392,131.32, representing a 68.58% increase from ¥594,606,181.26 at the end of the previous year[3] - Shareholders' equity attributable to the company was ¥922,977,118.32, up 76.09% from ¥524,138,056.37 at the end of the last year[3] - The total current assets increased to RMB 725,917,369.13 from RMB 314,929,356.70, showcasing a strong improvement in the company's short-term financial position[20] - The total non-current assets decreased slightly to RMB 276,474,762.19 from RMB 279,676,824.56, suggesting stability in long-term investments[20] - Total equity attributable to shareholders increased to CNY 922,977,118.32 from CNY 524,138,056.37, a significant rise of 76.1%[22] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 19,577[10] - The company has issued a total of 20,200,986 shares in its initial public offering, which was approved by the China Securities Regulatory Commission[17] Operational Highlights - The company plans to continue its market expansion and product development strategies, aiming for sustainable growth in the upcoming quarters[17] - The company is focusing on research and development of new products and technologies to enhance its competitive edge in the pharmaceutical industry[17] Donations and Subsidies - The company received government subsidies amounting to ¥770,553.18, which are closely related to its normal business operations[6] - The company made a donation of ¥1,000,000 to the Red Cross Society of Panshi City for epidemic prevention support[6] Other Financial Metrics - Total operating costs for Q1 2022 were CNY 44,475,693.43, down 14.4% from CNY 51,939,691.57 year-on-year[22] - Accounts payable increased to CNY 8,386,126.64 from CNY 6,235,531.98, reflecting a rise of 34.5%[21] - Other payables rose to CNY 27,186,912.80 from CNY 18,852,139.04, marking an increase of 43.8%[21] - Total liabilities amounted to CNY 79,415,013.00, up from CNY 70,468,124.89, indicating a growth of 12.8%[21] - Deferred income decreased slightly to CNY 35,008,213.57 from CNY 35,778,766.75, a decline of 2.1%[21] - The report for the first quarter was not audited, which may affect the reliability of the financial data presented[30]

Financial Performance - The company's operating revenue for 2021 was ¥285,655,932.11, a decrease of 0.23% compared to ¥286,318,719.28 in 2020[20]. - The net profit attributable to shareholders for 2021 was ¥52,019,092.21, representing an increase of 4.58% from ¥49,742,435.47 in 2020[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥44,997,813.13, up 6.06% from ¥42,427,354.94 in 2020[20]. - The net cash flow from operating activities for 2021 was ¥59,013,817.04, a decline of 8.56% compared to ¥64,541,781.89 in 2020[20]. - The total assets at the end of 2021 were ¥594,606,181.26, an increase of 7.96% from ¥550,760,343.90 at the end of 2020[20]. - The net assets attributable to shareholders at the end of 2021 were ¥524,138,056.37, reflecting an increase of 11.02% from ¥472,118,964.16 at the end of 2020[20]. - The basic earnings per share for 2021 were ¥0.8584, up 4.58% from ¥0.8208 in 2020[20]. - The diluted earnings per share for 2021 were also ¥0.8584, consistent with the basic earnings per share[20]. - The weighted average return on equity for 2021 was 10.44%, a decrease of 0.48% from 10.92% in 2020[20]. - The gross profit margin for the main pharmaceutical business was 83.67%, a decrease of 1.02% year-on-year[92]. - The company's main business revenue reached CNY 285.14 million, with a slight increase of 0.12% compared to the same period last year[92]. Dividend and Profit Distribution - The company reported a cash dividend of 1.30 RMB per 10 shares, totaling approximately 10.5 million RMB for all shareholders[6]. - The company implemented a stable profit distribution policy, prioritizing cash dividends, with a total cash dividend amounting to ¥10,504,512.59, which is 100% of the distributable profit[184][187]. - For the fiscal year 2021, the company achieved a net profit of ¥52,019,092.21[186]. - The cash dividend per 10 shares is set at ¥1.30 (including tax), based on a total share capital of 80,803,943 shares[187]. - The total distributable profit as of December 31, 2021, was ¥317,064,302.68[187]. - There were no stock dividends or capital increases from capital reserves during the reporting period[184][187]. Market and Industry Trends - The Chinese pharmaceutical market is projected to reach ¥17.29 billion in 2021, reflecting a recovery and growth trend post-pandemic[35]. - The company has identified significant growth opportunities in the pharmaceutical sector due to increasing healthcare spending and an aging population in China[38]. - The global pharmaceutical market is expected to continue growing, driven by population growth and aging demographics, with China being a key emerging market[31]. - The COVID-19 pandemic has significantly increased public awareness of diseases and health, potentially boosting pharmaceutical sales and improving treatment adherence for conditions like depression[40]. - The rise of internet healthcare channels since 2020 has enhanced drug accessibility, leading to a digital transformation in the pharmaceutical industry, which is expected to drive growth in chronic disease treatment[40]. - The pharmaceutical industry has high entry barriers due to strict regulatory oversight, ensuring orderly development and market access[41]. - The industry is characterized by high investment, high output, and high technology density, with significant government support for innovation and transformation[42]. Product Development and Innovation - The company is actively developing new products, including Ferrous Fumarate and Calcium Citrate, with ongoing quality standard enhancements and industrialization efforts[78]. - The company has a robust innovation-driven development strategy, continuously enhancing its technological capabilities and maintaining profitability over the years[54]. - The company has established a strong integrated advantage in "raw materials + formulations" after years of differentiated development[60]. - The company is committed to developing high-value-added products and promoting the scale and intensive development of the raw material drug industry over the next five years[59]. - The company has completed significant research on the quality standards of starting materials and is working on the industrialization of new products[104]. Risks and Challenges - The company highlighted risks including product concentration, policy changes due to pharmaceutical reforms, market competition, and operational risks from the COVID-19 pandemic[6]. - The company faces policy risks due to ongoing medical system reforms that may increase operational costs and alter business models[131]. - Environmental protection pressures may lead to increased costs and risks if the company fails to comply with national standards[134]. - The company relies on approved suppliers for raw materials, and any disruptions in supply could adversely affect production[134]. - The pharmaceutical industry is experiencing intensified internal competition, with more domestic and international companies entering the market, leading to a decline in average profit margins[136]. Corporate Governance - The company has established a comprehensive corporate governance structure in compliance with relevant laws and regulations, ensuring proper operational management[139]. - The company held one shareholders' meeting during the reporting period, adhering to all legal and procedural requirements[140]. - The board of directors consists of nine members, including three independent directors, meeting the legal requirements for composition[142]. - The supervisory board is composed of five members, ensuring compliance with legal and regulatory standards[143]. - The company emphasizes the importance of information disclosure and investor relations management, with a detailed management system in place[147]. Environmental Compliance - The company has implemented effective measures for wastewater treatment, with a treatment capacity of 200 cubic meters per day, ensuring compliance with environmental standards[196]. - The company utilizes high-efficiency dust removal systems with a removal rate of 90% for particulate matter and 95% for volatile organic compounds[196]. - All hazardous waste is managed properly, with 100% of hazardous waste being disposed of by a licensed environmental service provider[197]. - The company adheres to national environmental protection laws and regulations, ensuring that all pollutants are discharged in compliance with relevant standards[198]. - The company has established a robust internal control system, with the audit report aligning with the board's self-evaluation[192].